Improving Medication Prescribing-Related Outcomes for Vulnerable Elderly In Transitions on High Risk Medications (IMPROVE-IT HRM): A Pilot Randomized Trial Protocol

Anne Holbrook (Principal Investigator), Dan Perri (CMIO, SJHH), Mitch Levine, Sarah Jarmain (SJHH Chief of Staff - Decision Maker), Lehana Thabane, Jean-Eric Tarride, Lisa Dolovich, Sylvia Hyland (ISMP Decision Maker), Alan Forster, Carmine Nieuwstraten (Collaborator).

Patient Advisory Committee: Melissa Sheldrick, Jeanette Smith, David Patterson

ClinicalTrials.gov Identifier: NCT04077281

Funded by Canadian Institutes of Health Research, Funding Reference Number TEG-165595

## **ABSTRACT**

Rationale: Transitions in, through, and out of hospital define the highest risk periods for patient safety. Hospitalized senior high-cost health care users taking high risk medications, are a large group of patients, usually highly complex with polypharmacy, and at high risk of serious adverse medication events. We will assess whether an expert Clinical Pharmacology Toxicology (CPT) medication management intervention during hospitalization with follow-up post-discharge and communication with circle of care, is feasible and can decrease drug therapy problems amongst this group.

**Design:** Pragmatic pilot randomized trial at SJHH with 1:1 patient-level concealed randomization with blinded outcome assessment and data analysis.

**Participants:** Adults 65 years of age and older, admitted to Internal Medicine services for more than 2 days, who are high-cost users defined as at least one other hospitalization in the prior year, taking 5 or more chronic medications including at least one high risk medication.

**Intervention:** CPT consult service identifies medication target(s), completes consult, including priorities for improving prescribing negotiated with the patient, starts the care plan, ensures a detailed discharge medication reconciliation and circle-of-care communication, and sees the patient at least twice after hospital discharge via integrated virtual visits to consolidate the care plan in the community. Control group receives usual care as provided by admitting services.

**Outcomes:** Include a) Feasibility Outcomes and b) Clinical Outcomes including the number of drug therapy problems improved, medication appropriateness and safety, the quality and coordination of transitions in care, quality of life, and health care utilization and costs by 3-month follow-up.

**Impact:** If results support feasibility of ramp-up and promising clinical outcomes, a follow-up definitive trial will be organized using a developing national platform and medication appropriateness network.

## RESEARCH QUESTION

Our detailed research question is 'In a randomized pilot trial, can an expert Clinical Pharmacology team coordinate and improve medication management during the very high-risk transition period from hospitalization through post-hospital discharge follow-up for senior high-cost users of healthcare taking high risk medications, meeting key feasibility outcomes while improving patient-important outcomes and health care costs sufficiently to warrant a large subsequent trial?'

#### INTRODUCTION

Current systematic reviews of randomized trials to manage polypharmacy or to manage medications in hospital or in the transitions of care have been unable to demonstrate improvements in important clinical outcomes. This is largely because a) the interventions have been led by providers without the requisite combination of diagnostic, therapeutic and risk management expertise or authority to make requisite changes, b) the intervention was not sufficiently concentrated (too short, incomplete or misdirected), c) the medication focus was misplaced (i.e., not high-risk medications, which are the most associated with adverse clinical outcomes) or the outcomes were overly focused on poor quality surrogates for clinical outcomes.

Because of the huge potential burden of harm and the number of affected vulnerable older adults in our population (details below), the value of more randomized trial inquiry is very high. There is enough suggestion of benefit from trials on prescribing appropriateness combined with the potential for major medication safety improvements, 4,6-9 to support an expert intervention concentrated on the highest risk group as they transition through a very high-risk period targeting the highest risk medications. In addition, recent advances in digital health in Canada make it feasible for scarce clinical expertise to be concentrated on this high priority problem with robust communication systems that support patient consultation and follow-up to any part of country no matter how remote.

#### Medication Safety is an International Health Priority

In 2017, the World Health Organization (WHO) declared Medication Safety to be its current Global Patient Safety Challenge, with a specific focus on improving poor processes and procedures. <sup>10</sup> Their three categories for early priority action include high-risk situations (eg, hospitals and high alert medications), polypharmacy, and transitions of care. *We will address all three of these key categories in this project.* 

## High Risk Medication Safety Situations Are Known

Transitions in Care, particularly in and out of hospital and High Alert Medications, are two primary high risk situations referenced by WHO. <sup>10</sup> Even with evidence of under-detection, systematic reviews of the literature conclude that adverse drug events (ADEs) amongst older adults lead to approximately 1 in 10 hospitalizations. <sup>11-13</sup> Canada-wide data suggest that adverse drug-related hospital admissions are directly correlated with the number of medications taken concurrently, the number of prescribers involved, possibly the number of pharmacies used, and to hospitalization within the previous year. <sup>14</sup> In several studies, female sex was also a risk factor.

Once in hospital, patients (n=46,626) remain at high risk of ADEs, with a mean prevalence of 21.6% (SD 16.7,), 20.7% of these judged to be severe or life-threatening and 32.3% (SD 22.6%) judged to be preventable. In addition to the risk factors above, a complex patient (several comorbidities with several provider experts involved) is significantly more likely to suffer adverse events in hospital. In Canada, medical and surgical services, because of the older age, high complexity and volume of patients seen, have the highest rates of adverse events overall.

The period immediately following hospital discharge remains high risk with 37% of seniors sustaining

medication-related harm (81% serious) within 8 weeks.<sup>18</sup> In this systematic review, female sex was associated with medication-related harm.<sup>18</sup> This leads to frequent readmissions and high costs. The outcomes of ADEs included prolonged length of stay, frequent readmission, emotional trauma, high costs, and death.<sup>16</sup>, <sup>19</sup>, <sup>20</sup>

# Polypharmacy and Potentially Inappropriate Prescribing (PIP) Are Important Signals

The term "polypharmacy" has multiple definitions, but the most common is the concurrent use of 5 or more medications daily by a single individual.<sup>4</sup> The prevalence of polypharmacy in Canada is very high amongst seniors, at approximately 66%, with 27% of these taking 10 or more medications concurrently, a situation we label major polypharmacy.<sup>4, 21</sup> While the number of medications used remains a useful signal, it is impossible to gauge the quality of medication regimens simply by the number of medications, as this does not account for the patient's main diagnosis, comorbidities, risk factors, past history of medication use, or the benefit-harm ratio of the drug for that patient. For example, an older patient with diabetes frequently requires two glucose lowering medications, a statin for cholesterol, and two to three medications for blood pressure, just to manage their high cardiovascular risk without treating their other health problems. Thus, the medication safety target is problematic polypharmacy as opposed to appropriate polypharmacy.<sup>22</sup>

Medications which frequently lead to harms outweighing benefit in certain situations are termed 'potentially inappropriate medications' (PIMs). PIMs that have been associated with ADEs have been grouped together in medication screening lists, with the most evidence-based being the **STOPP** criteria.<sup>23</sup> Randomized trials in Europe show that use of the STOPP criteria as a trigger for medication review for hospitalized seniors can improve the appropriateness of prescribing, reduce ADEs and reduce length of stay.<sup>24, 25</sup> A cross-Canada study found that nearly 40% of seniors fill a prescription for at least one PIM per year, with the highest rates in women > 85 years of age and the most common PIM drug category being sedative-hypnotic drugs.<sup>26</sup> The cost of these PIMS plus the cost of treating their adverse effects has been estimated to be more than \$1.8 billion every year in Canada.<sup>26</sup>

#### Interventions Should be Focused on Priority Areas

## A. Priority Medications

Although STOPP is an excellent screening tool, there are too many alerts (80 in current iteration) to feasibly apply in hospitalized patients where timely discharge is a high priority. Analyses of Canadian and U.S. data on medication utilization and drug-related causes of hospitalization by our group and others, suggest recurring groups of very commonly, widely used medications as the main causes of drug-related hospitalizations. These are all medication families with proven benefit of varying clinical importance but also clinically important harm when not managed expertly. Thus, these are medications that should trigger review of the entire medication regimen to consider improvements. We have labelled these the high risk medications (HRM):

- i. Anticoagulants,
- ii. Analgesics including Opioids, NSAIDs and Glucocorticoids,
- iii. Antimicrobials,
- iv. Antineoplastic agents,
- v. Glucose-lowering drugs for diabetes,
- vi. Cardiac drugs including Diuretics and Digoxin,
- vii. Sedative-hypnotics including Benzodiazepine receptor antagonists,
- viii. Antipsychotic agents

Further details are included in Appendix 1. In many cases, the high-risk medication itself (e.g., anticoagulant, glucocorticoid, glucose lowering medication, antineoplastic agent, etc) is required for the patient but the dose may require adjustment, a tapering regimen might be appropriate, or a review for potentially serious drug interactions or medication burden identifies another medication that can be removed to decrease the patient's

overall risk of medication-related harm. We have previously developed an 'Appropriateness of Prescribing Evaluation Questionnaire' that has become the standard, holistic, medication appropriateness assessment tool.<sup>29,30</sup> Our ongoing development work suggests that while optimization of the high risk medications is feasible, it also opens up other opportunities for important improvements in medication management, including removal of medications and supplements with no benefit or with possibility of contamination, or substitution of more cost-effective alternatives.

#### B. Priority Patients

So-called high cost users (HCUs) have been an international priority target for quality and cost of care improvements for years.<sup>31</sup> In a series of large population-based observational studies, we have shown that 5% of Ontarians generate 65% of the entire health care costs, approximately 70% of these are seniors (> 500,000), and these are complex patients with multiple hospital admissions, multiple providers, multiple diagnostic labels and problematic polypharmacy.<sup>32-34</sup> Use of high-risk medications is very prevalent in this population and strongly predictive of future healthcare utilization and mortality in a dose- and duration-dependent manner compared to non-users.<sup>32-35</sup>

## C. Priority Situations

Senior HCUs taking high-risk medications who are transitioning in, through, and out of hospital are at very high risk of serious ADEs. Hospitalization is a double-edged sword in that it defines high risk situations but also houses the expertise required to effectively intervene. This opportunity to optimize medication regimens for these inpatients is widely underutilized worldwide, due to a) huge pressures to just deal with the main problem requiring admission and get the patient discharged as quickly as possible due to bed shortages and b) lack of expertise amongst general medicine and surgery admitting services to complete an expert medication assessment quickly. In preparation for this trial, we recently completed a chart review of 100 randomly selected senior HCUs who were admitted to a Hamilton hospital (mean age 82 years), and found the mean rate of potentially inappropriate medications to be 2.8 per person. Only 16.6% of these had been addressed by the time of discharge.<sup>36</sup>

#### Medication Safety Interventions Worth Evaluating

Two areas of innovation, heretofore not available for use in Canada, have matured sufficiently to be potentially effective, cost-effective, and highly feasible.

# A. Innovation in Digital Health

The ability to date of digital health solutions, including electronic health records (EHRs) to meet the demands and complexity of modern medicine has been underwhelming.<sup>37</sup> However, all patient safety leadership organizations including the Institute for Safe Medication Practices (ISMP), the Canadian Patient Safety Institute (CPSI), and the Agency for Health Care Research and Quality, agree that EHRs must be part of the medication safety solution, as system factors in addition to human factors, are always amongst the key root causes of adverse events. <sup>38-40</sup>

<u>Epic</u> is a world-leading EHR software. It has won the Best in KLAS award for healthcare software suites 8 years in a row and is the EHR for the 20 top hospitals and the 20 top graduate schools for medical research in the United States. 41, 42 St Joseph's Healthcare Hamilton is the first large academic hospital system in Canada to go live (in 2017) with a build called Dovetale-Epic. 43 This installation of Epic has led to rapid *innovation in both Clinical Care and in Research*.

Clinical Care advances relevant to this project include a) automated patient risk screening abilities, b) medication management alerts, c) improved physician- pharmacist communications, d) ability to easily maintain and connect an organized 'circle of care' for the patient (hospital and community providers, family, caregivers), and e) fully integrated telemedicine/telehealth compatible with a patient's smart phone which facilitates and documents 'virtual visit' follow-up in the patient's home. This technology extends the consultation reach of scarce, valuable specialties such as Clinical Pharmacology and Toxicology (CPT) to anywhere in Canada.

Research innovation includes novel major efficiencies in a) recruiting for trials, and b) quality and efficiency improvements in data collection and capture using secure transfer to industry-standard research data platforms (REDCap). Although a long time coming, EHRs have tremendous potential to improve the quality (richer data) while reducing the cost of RCTs.<sup>44</sup> Since virtually all of the leading medical centres for clinical care and research in the United States use Epic, and several large additional hospital installations are imminent in Canada, this project will serve as a prototype pilot for a very large international research network serving a population of more than 150 million people.

#### B. Innovation in Clinical Expertise

Clinical Pharmacology and Toxicology (CPT) is one of the newest and smallest Royal College of Physicians - certified specialties in Canada. Its key mandate is improving the quality of drug therapy from bench to bedside to policy. Hamilton's clinical pharmacologists who are also certified in Internal Medicine are unique in Canada in their ability and depth of experience in caring for complex elderly patients on multiple medications in need of evidence-informed review while in hospital and in follow-up. Their training and supervisory expertise has been recognized with multiple awards, and includes building capacity amongst trainees who will work elsewhere. In addition, the drug policy and formulary decision-making that is crucial to guiding cost-effective prescribing, is heavily influenced by CPT.

#### **METHODS**

#### Design

Pragmatic pilot randomized trial (RCT) at SJHH with 1:1 patient-level concealed-allocation randomization with blinded outcome assessment and data analysis. Randomization provides the highest quality methods to minimize bias, the pragmatic design ensures relevance to clinical practice essential for implementation, and a pilot RCT addresses feasibility of a large definitive subsequent RCT directly without waste of research dollars. <sup>46, 47</sup> A study flow diagram is shown below in Figure 1.

#### **Participants**

Adults over the age of 65 years who are admitted to Medicine services for more than 2 days, who are high cost users defined as at least one other hospitalization within the previous year, who are taking 5 or more chronic medications including at least one high risk medication and provide informed consent. It is estimated that at least ten patients daily meet these eligibility criteria.

# Recruitment and Randomization

The Research Institute of St Joes Hamilton recently approved a policy that every patient admitted can be approached to participate in studies unless they decline (Access Research). Dovetale-Epic tracks this 'may approach/do not approach' status for each patient in real time. This effectively alleviates a barrier as the (usual) necessity of relying on the patient's core team to refer a potentially eligible patient is a major barrier to recruitment, simply due to distraction of the team with the clinical priorities.

We are working with the Dovetale team to have all potentially eligible patients screened for age, HCU status (defined as at least one previous admission in the prior year) and the presence of five or more chronic (not prn) medications with one or more high risk medication. Screen eligibility-positive patients will be posted to the current Clinical Pharmacology and Toxicology team's intake list. Once eligibility is confirmed, the ward pharmacist will ensure that an accurate BPMH (best possible medication history) is completed and documented appropriately in Dovetale-Epic. An accurate BPMH is critical for an accurate discharge medication reconciliation. Research staff will check with the most responsible physician (MRP) team regarding eligibility (this stage picks up on delirium and dementia, for example). The research team will then approach the patient to invite participation, introduce the study and complete the informed consent process which includes answering questions, completing a short Capacity to Consent questionnaire (Appendix 2), and Informed Consent document.<sup>48</sup>

Patients with cognitive impairment will not be excluded as they constitute a vulnerable group in need of

assistance, but they must have a primary caregiver who assists them with medications and who is willing to sign informed consent if the patient fails the Capacity to Consent questionnaire.<sup>48</sup> For this pilot trial, either the patient or caregiver must be fluent in English.

Patients will be randomly allocated to the intervention or control arms in a 1:1 ratio in permuted blocks using a statistician-formulated randomization schedule that will be available online 24/7.

A validated patient frailty index will be incorporated at baseline as a prognostic marker<sup>49</sup>.

## Intervention

Our intervention follows the general Innovative Practices framework recommended by Health Quality Ontario for Transitions between Hospital and Home, and uses the specific approach in Figure 2.<sup>50</sup>

## CPICS (Clinical Pharmacology Inpatient Consult Service) Notification

Randomization to the intervention arm will trigger a request for a CPT (Clinical Pharmacology & Toxicology) consult, using our Clinical Pharmacology Inpatient Consult Service (CPICS) workflow. The CPT team consists of a unique combination of expert Clinical Pharmacologists (Royal College physician specialist in patient assessment and diagnosis, drug therapy, adverse drug events, drug access, safe prescribing, cost-effective medication management) with additional expertise in evidence-based geriatric prescribing, multi-morbidity, and de-prescribing; medicine and pharmacy trainees; and a research assistant. There are fewer than 20 such CPT specialists in Canada, four of them located at SJHH with the largest cumulated experience of any medical centre at more than 90 physician-years.

#### Initial Consult

The initial CPT consult for each patient includes a comprehensive patient assessment including demographics, social situation, drug coverage insurance, functional status (activities of daily living, instrumental activities of daily living), cognition, frailty markers, level of caregiver involvement, past medical history and current problems, allergies and intolerances, detailed medication history including reminder aids and methods of accessing medication, physical exam and review of current and historical laboratory and diagnostic imaging results. These details are structured data items in EPIC behind a customized CPT consult, progress or discharge note structured template, which ensures consistency of intervention across the four consultants.

In addition, the CPT team will document a detailed 'circle of care' for each patient (their primary caregiver, hospital MRP team, family doctor, community physician specialists, community pharmacists and home care), and will identify all potential high-risk medications targets that the patient is taking or is due to resume post-hospitalization. Using patient preference elicitation methods and motivational interviewing, priorities for medication optimization will be negotiated.<sup>51-56</sup> Short patient infographics endorsed by the Canadian Medication Appropriateness and Deprescribing Network (CADeN) will be used as educational materials.

#### CPICS Follow-up

While the patient is still hospitalized, the high-risk medications care plan begins and the team ensures close communication with the MRP (Most Responsible Physician) admitting team, coordinates a detailed discharge medication reconciliation (documenting medication changes with rationale, formulating an accurate discharge prescription including rapid access to new medications), ensures circle-of-care communication and sees the patient via Virtual Visit twice in follow-up at 1 week and 1 month after hospital discharge to complete the care plan.

#### Control

These patients will receive usual care by their primary team. This means that the MRP team is responsible for coordinating medication management at discharge and post-hospital follow-up, as is currently practiced.

#### Outcomes

The Core Outcome Set for Interventions to Improve Polypharmacy in Older People was consulted to assist

with our selection of outcomes.<sup>57</sup> Core outcome sets are consensus-based guidelines from groups of clinicians, patients and methodologists on which outcomes with which metrics, are the most important to be measured in prospective studies.<sup>58</sup> In addition, we consulted other polypharmacy/deprescribing trials for recommended patient-important outcomes.<sup>59-64</sup>

For this pilot RCT, we will analyze outcomes according to a set of Primary and Secondary Outcomes. (see details in Table 1 and Table 2.)

<u>Primary Outcomes</u>. There are two types of primary outcomes that will be evaluated:

- a) The *Primary Feasibility Outcomes* will be recruitment and retention rate for eligible patients, and the estimated resources required per patient to complete the main trial. We aim for at least 30% recruitment of those eligible, 90% retention of those recruited, and no more than \$1500 per patient spent on running the pilot trial.
- b) The *Primary Clinical Outcome* will be the number of drug therapy problems improved including the number of high-risk medications improved (for example, dose adjustment, discontinued, seriously interacting drugs removed) at 3 months post- hospital discharge end-study visit.

## **Secondary Outcomes:**

- a) The Secondary Feasibility Outcomes of CPT consultation include: CPICS recommendation acceptance by primary team and by patients, consult volume capacity, and potential to apply the intervention entirely through virtual visits.
- b) The Secondary Clinical/Patient-important outcomes will include:
  - 1. Other medication management outcomes (details in Table 1)
  - 2. Adverse drug events using the standard definition of harm caused by use or inappropriate use of a drug, and including rating of preventability using the 'best practice'-based definition of Woo et al inappropriate drug or dosage or route or frequency of a drug given the patient's age, diagnoses, weight, organ function; or administration of a drug for which the patient has a major allergy or intolerance; or inappropriate laboratory monitoring. <sup>65</sup> Specific rating of ADE will use the standard Leape and Bates scale: 6- definitely due to medication, 5- probably due to medication, 4- possibly due to medication, 3- possibly due to disease, 1- definitely due to disease.
  - 3. Medication errors characterized as errors in prescription, dispensing, or administration using standard NCC-MERP definitions and classification.<sup>67</sup> A Medication Error is an error (of commission or omission) at any step along the pathway that begins with prescribing and ends with the patient taking or not taking the medication. <sup>68</sup>
  - 4. Patient Problems with Medications: The COMPETE Medication Problems Questionnaire measures problems with medication access, handling, beliefs and adherence.<sup>69</sup>
  - 5. Medication Knowledge Assessment: this will be assessed using the Medication Knowledge Assessment form, which tests knowledge of medication name, indication, dosage instructions, and precautions.<sup>70</sup>
  - 6. Coordination and Continuity of Care: Adapted from Health Quality Ontario's draft guidance and a Rand instrument, the Coordination and Continuity of Care Questionnaire is designed to measure the quality of the transitional and follow-up care. We will focus on medication reconciliations and education, and circle of care communications.<sup>71,72</sup>
  - 7. Patient Quality of Life: The EQ-5D-5L is the 5-level classification system of the EQ-5D, a measure of health status from the EuroQol Group, which also contributes incremental utility values to the cost-effectiveness evaluation. Using EQ-5D-5L, respondents are asked a short series of questions about mobility, self-care, usual activities, pain discomfort, and anxiety/depression, as well as a summary visual analogue scale. This scale, which provides utility measurements, has been well validated for the Canadian population. We will also use a 'condition-specific' QOL measure, the Medication-related Quality of Life measure which is designed for people with polypharmacy.

- 8. Satisfaction with Care: Satisfaction reported by patients and by key health professionals is one of the recommended outcomes to report in medical research, as it may influence adherence.<sup>77, 78</sup> This outcome will be assessed by the Patient/Caregiver Study Satisfaction Survey and by the Provider Study Satisfaction Survey.<sup>79</sup>
- 9. Health Resource Utilization: This is a key outcome to determine cost-effectiveness and cost-utility which then determines whether health care systems might pay for this type of care. <sup>80, 81</sup> To improve accuracy and feasibility, we will estimate costs based on healthcare utilization, concentrating on Emergency Department visits, hospitalizations, unplanned physician visits and medication costs, including out-of-pocket medication costs in follow-up. <sup>72, 81</sup>. The analysis will follow the guidance of international and Canadian guidelines. <sup>82, 83</sup>

Outcomes will be collected through a mix of patient interview and chart review. The impact of sex, gender, age, social support, socioeconomic status, cognition, number of medications, and location of discharge, will be examined as potential interaction variables with the intervention and as predictors of outcomes. Sensitivity analyses will assist with determination of potential for cost-effectiveness of the intervention overall and in selected subgroups.

Geographic wards in the hospital allow for evaluation of the intra-cluster correlation (ICC), which based on past experience, we expect to be low. If ICC proves to be high, more complex cluster RCTs will be required. Additionally, barriers and facilitators to success of the primary outcomes, in terms of process and management issues will be evaluated. These will be used to determine whether a large definitive research study is likely to be feasible, taking into account the practical aspects of managing and funding the project.

## Follow-up

Patients will be followed until three months post-hospital discharge or until death, whichever occurs first. The challenges and uncertainties posed by the COVID-19 pandemic have highlighted the role and importance of telemedicine, which this trial will utilize for patient follow-up visits. These visits will be conducted by videoconference via Dovetale-Epic or Ontario Telehealth Network, or by phone call, depending on the patient's digital technology capability.

## Sample size

Our calculations, based on two independent study groups, measuring a continuous primary outcome, allowing a probability of a Type 1 error of 5%, suggest that to have 80% power to determine an improvement in number of drug therapy problems improved from 3 (Standard deviation 1.4) to 2.5, would require a total sample size of 248 or 124 per group. 84. Since this is a pilot RCT, we will aim for 30 patients per group or 60 in total as this number is likely to provide adequate evidence regarding feasibility for ramp-up and actual sample size.

## Allocation

Participants who meet all the inclusion/exclusion criteria at screening and have completed informed consent will be enrolled in the study, complete baseline assessments, then will be randomized via a computer-generated randomization sequence to one of the two study arms, intervention or control.

A statistician will prepare the randomization schedule. <sup>85</sup> The pilot is being carried out at a single site, although an eventual trial will be multicentre. <sup>86</sup> To restrict treatment group imbalance a maximal tolerable imbalance between treatment groups will be incorporated into the schedule. <sup>87</sup> The randomization schedule will be produced by a program written in R and implemented in REDCap where each patient's treatment assignment will be available on-line to the research staff only at the time of randomization. This process ensures allocation concealment, and randomization awareness where necessary, for example for the intervention staff.

#### Blinding

Since this is a pragmatic RCT, it will not be possible to completely blind patients or their providers, however outcome data collectors, adjudicators and statisticians will be blinded to group allocation until analysis is completed at the end of the study.

## **Data Collection Methods**

Trained research staff will conduct the interviews with the patients or caregivers, entering data electronically on study laptops directly into REDCap case report forms. The participants' medical records will be reviewed to abstract data on baseline characteristics, medical history, and medication information. Strategies to promote participant retention and complete follow-up include reminding participants in advance of their end-of-study visit and communicating by email if email address is provided at baseline. Participants who drop out of the study will have their data to that point retained in the study, as approved by REB, to avoid bias. The reasons for study non-completion will be recorded.

## Data Management

REDCap (Research Electronic Data Capture) is our study software platform – secure, web-based, providing interfaces for validated data capture, role-specific access, audit trails for tracking data manipulation and exports, automated export procedures to SAS and encrypted transmissions. Repeat the study documents including signed informed consent forms will be stored in our secure research office once they are scanned into REDCap study files. Regular data quality checks, such as automatic range checks, will be performed by the study team to identify data that appear inconsistent, incomplete, or inaccurate.

Patients are not identifiable in the project results database. The identifying information required for the clinical team to deliver the intervention is kept in a separate database. Access to the final dataset will be restricted to the core research team.

#### Statistical Analyses

The reporting of the results of this trial will follow the CONSORT extension for pilot trials. <sup>90</sup> We will use descriptive statistics for presentation of baseline variables and adequacy of follow-up. Feasibility analysis including recruitment rate (≥30% is considered success), participant retention rate (≥90% to end of study is considered success), study resource utilization required (less than CAD \$1500 per patient recruited), management assessment, and scientific assessment, will be descriptive.

Analysis will use intention-to-treat methods with censoring only if the patient dies or drops out of the study with refusal of negotiated further assessments. A sensitivity analysis of the subgroup of patients who received all planned follow-up intervention calls and completed the end-study data collection (per protocol analysis), will be carried out. Research staff and statisticians will review outcome data and analysis blinded to group identification.

The primary clinical endpoint will be number of drug therapy problems improved including the number of high-risk medications improved, as measured by chi-squared and t-tests. Secondary endpoint analyses of the coordination and continuity of care, patient quality of life, medication knowledge, satisfaction with care (providers & patients), and resource utilization, will be analyzed using t-tests. The incidence of the adjudicated individual clinical events (all-cause hospitalizations and emergency department visits) will be analysed using the methods described above for drug therapy problems. Public unit costs from Ontario will be used to cost healthcare resource utilization collected as part of the trial. Using an area under the curve approach, quality adjusted life years (QALYs) will be determined by weighting the EQ-5D-5L health utility scores by time spent in health state. Costs and outcomes (i.e., QALYs, adverse clinical events) between the groups will be compared from a public payer perspective.

Given the short follow-up, low risk of the trial and pilot design, no interim analysis or imputation for missing data is planned. All statistical analyses will be performed using SAS V9.4 software (SAS Institute Inc., Cary, NC, USA).

## **Data Monitoring**

Any serious adverse event will be reviewed by our Trial Steering Committee (TSC) within a week of detection, to discern any attribution to our procedures. If found to be due to our coordination procedures, the trial steering committee will recommend whether modifications are indicated. The TSC will be composed of individuals with expertise in clinical trials, chaired by the lead statistician, include the PI, the operational statistician plus a methodologist independent of the study team. Similarly, since this is a short pilot pragmatic RCT where no

harm is expected and adjustment of trial procedures may be necessary for feasibility, no formal external auditing of trial conduct is planned. There is no requirement for additional ancillary and post-trial care for those who might come to harm while in the trial, as usual medical care which covers this eventuality is already in place.

# Privacy and Confidentiality

Study data will be entered into REDCap, which is a secure database, and access to REDCap will only be provided to approved research staff who are trained in general research guidelines (i.e. GCP, TCPS2, privacy tutorial). Patient identifiers will be stored in a separare REDCap folder with limited access. All data on the REDCap server is encrypted and all access is audited. A paper copy of the link between study ID and patient identifiers will be stored in a locked cabinet in a locked cabinet inside our locked research offices in the hospital, which is accessed only by our research staff. This link, both paper and electronic, will be destroyed at the end of the study. Any other hard copies of study related information (i.e. signed Informed Consent Forms), will be transported within SJHH by the research staff and stored in our secured offices. Patients will be assigned a study ID that will be recorded on their CRFs and no direct identifiers will be used on the Case Report Forms.

#### IMPACT OF RESEARCH

By using an integrated KT approach with clinicians, patients, researchers, drug policy advisors, information technology advisors, quality improvement advisors, and hospital and national medication safety administrators involved in the project from protocol to dissemination, we hope to strengthen and broaden the usual dissemination of research to practice and policy. However, this is a pilot study, so the main dissemination question will revolve around whether there is sufficient value to justify a larger, definitive clinical trial. Given the major improvements in research efficiency and international research product dissemination that EPIC affords us, we will be cultivating a Canadian EPIC-based research network amongst the impending participating hospitals.

#### **ETHICS**

The study has been approved (study #7598) by Hamilton Integrated Research Ethics Board. Significant protocol modifications will be proactively communicated to the research ethics boards through study amendments to obtain approval prior to the changes being implemented. Each modification will be assessed to determine whether it warrants communication with trial participants.

#### **REFERENCES**

- 1. Rankin A CC, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9(9):CD008165.
- 2. Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2016;2:CD008986.
- 3. Redmond P, Grimes TC, McDonnell R, Boland F, Hughes C, Fahey T. Impact of medication reconciliation for improving transitions of care. Cochrane Database Syst Rev. 2018;8:CD010791.
- 4. Anderson LJ, Schnipper JL, Nuckols TK, Shane R, Sarkisian C, Le MM, et al. A systematic overview of systematic reviews evaluating interventions addressing polypharmacy. Am J Health Syst Pharm. 2019;76(21):1777-87.
- 5. Johansson T, Abuzahra ME, Keller S, Mann E, Faller B, Sommerauer C, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(2):532-48.
- 6. Gray SL, Hart LA, Perera S, Semla TP, Schmader KE, Hanlon JT. Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults. J Am Geriatr Soc. 2018;66(2):282-8.
- 7. Le Berre M, Maimon G, Sourial N, Gueriton M, Vedel I. Impact of Transitional Care Services for Chronically Ill Older Patients: A Systematic Evidence Review. J Am Geriatr Soc. 2017;65(7):1597-608.
- 8. Kastner M, Cardoso R, Lai Y, Treister V, Hamid JS, Hayden L, et al. Effectiveness of interventions for managing multiple high-burden chronic diseases in older adults: a systematic review and meta-analysis. CMAJ. 2018;190(34):E1004-E12.
- 9. Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, et al. Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(3):375-82.
- 10. WHO. Medication Without Harm: WHO; 2017 [Available from: <a href="https://www.who.int/initiatives/medication-without-harm">https://www.who.int/initiatives/medication-without-harm</a>.
- 11. Oscanoa TJ LF, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly: A meta-analysis. Eur J Clin Pharmacol. 2017;6:759-70.
- 12. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079-86.
- 13. Hohl CM, de Lemos J, Abu Laban RB. Emergency hospitalizations for adverse drug events. N Engl J Med. 2012;366(9):858-9; author reply 9-60.
- 14. Canadian Institute for Health Information. Adverse Drug Reaction–Related Hospitalizations Among Seniors, 2006 to 2011: CIHI; 2013 [Available from: www.cihi.ca.
- 15. Laatikainen O, Miettunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol. 2017;73(12):1539-49.
- 16. Chan B CD. Measuring Patient Harm in Canadian Hospitals. With What can be done to improve patient safety? : Canadian Institute for Health Information (CIHI); 2016 [Available from: <a href="https://www.cihi.ca">www.cihi.ca</a>.
- 17. Institue for Safe Medication Practices Canada. Ontario Hospital Critical Incidents Related to Medications or IV Fluids Analysis Report: October 2011 to December 2012: ISMP; 2013 [Available from: www.ismp-canada.org.
- 18. Parekh N, Ali K, Stevenson JM, Davies JG, Schiff R, Van der Cammen T, et al. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. Br J Clin Pharmacol. 2018;84(8):1789-97.
- 19. Amelung S, Meid AD, Nafe M, Thalheimer M, Hoppe-Tichy T, Haefeli WE, et al. Association of preventable adverse drug events with inpatients' length of stay-A propensity-matched cohort study. Int J Clin Pract. 2017;71(10).
- 20. Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain CM, Bereznicki LR. Repeat Adverse Drug Reaction-Related Hospital Admissions in Elderly Australians: A Retrospective Study at the Royal Hobart Hospital. Drugs Aging. 2017;34(10):777-83.
- 21. Canadian Institute for Health Information. Drug Use Among Seniors on Public Drug Programs in

- Canada 2012: CIHI; 2012 [Available from: www.cihi.ca.
- 22. Duerden M AT, Payne R. Polypharmacy and Medicines Optimisation: Making it Safe and Sound. UK: Kings Fund; 2013.
- 23. Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013-9.
- 24. Gallagher PF, O'Connor MN, O'Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011:89(6):845-54.
- 25. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-8.
- 26. Morgan SG, Hunt J, Rioux J, Proulx J, Weymann D, Tannenbaum C. Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. CMAJ Open. 2016;4(2):E346-51.
- 27. Bayoumi I, Dolovich L, Hutchison B, Holbrook A. Medication-related emergency department visits and hospitalizations among older adults. Can Fam Physician. 2014;60(4):e217-22.
- 28. Budnitz DS, Shehab N, Lovegrove MC, Geller AI, Lind JN, Pollock DA. US Emergency Department Visits Attributed to Medication Harms, 2017-2019. JAMA. 2021;326(13):1299-309.
- 29. Holbrook A JV, Goldsmith CH, Shcherbatykh IY, COMPETE Investigators. A comprehensive appropriateness of prescribing questionnaire was validated by nominal consensus group. J Clin Epidemiol. 2007;10(60):1022-8.
- 30. Holbrook A KK, Troyan S, Goldmith C, Smiley T, Nabzdyk K. Measuring the appropriateness of prescribing. Can it be explicit and evidence-based? Can J Clin Pharmacol. 1999;6(44).
- 31. Lee JY, Muratov S, Tarride JE, Holbrook AM. Managing High-Cost Healthcare Users: The International Search for Effective Evidence-Supported Strategies. J Am Geriatr Soc. 2018;66(5):1002-8.
- 32. Lee J MS, Tarride J-E, Paterson JM, Thavorn K, Mbuagbaw L, Gomes T, Khuu W, Seow H, Thabane L, Holbrook A. Medication use and its impact on high-cost health care users among older adults: protocol for the population-based matched cohort HiCOSTT study. CMAJ Open. 2011;9(1):E44-52.
- 33. Muratov S LJ, Holbrook A, Paterson JM, Guertin JR, Mbuagbaw L, et al. Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. CMAJ Open. 2019;3(7):E537-E45.
- 34. Muratov S, Lee J, Holbrook A, Guertin JR, Mbuagbaw L, Paterson JM, et al. Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. BMJ Open. 2019;9(10):e028637.
- 35. Lee J MS, Tarride J, Paterson J, Thavorn K, Mbuagbaw L, et al. Medication Predictors of High Cost Healthcare Use Among Older Adults. Canadian Association for Health Services and Policy Research (CAHSPR) Conference; May 29-31; Montreal, QC2018.
- 36. Sanh M HA, Macdonald P, Lee J. Potentially Inappropriate Prescribing in Hospitalized Older Adult High-Cost Health Care Users: A Pilot Study. The Canadian Journal of Hospital Pharmacy. 2022;75(3).
- 37. Zhao EJ. The future of electronic medical records in Canada. CMAJ. 2019;191(19):E542.
- 38. Agency for Healthcare Research and Quality. 10 Patient Safety Tips for Hospitals: Agency for Healthcare Research and Quality; 2018 [Available from: <a href="http://www.ahrq.gov/patients-consumers/diagnosis-treatment/hospitals-clinics/10-tips/index.html">http://www.ahrq.gov/patients-consumers/diagnosis-treatment/hospitals-clinics/10-tips/index.html</a>.
- 39. Canadian Patient Safety Institute (CPSI). Improving Medication Safety Canada: CPSI; 2021 [Available from: https://www.patientsafetyinstitute.ca/en/Topic/Pages/Improving-Medication-Safety.aspx.
- 40. Institue for Safe Medication Practices Canada. Electronic Prescribing in Primary Care: Effects on Medication Safety. Canada; 2018.
- 41. B M. Epic Systems lands Best in KLAS award 8th year in a row: Healthcare IT News; 2018 [Available from: <a href="https://www.healthcareitnews.com/news/epic-systems-lands-best-klas-award-8th-year-">https://www.healthcareitnews.com/news/epic-systems-lands-best-klas-award-8th-year-</a> row.
- 42. EPIC [Internet]. 1979 [cited 2017]. Available from: https://www.epic.com/about.
- 43. Dovetale [Internet]. St. Joseph's Healthcare Hamilton. 2017.
- 44. Mc Cord KA HL. Using electronic health records for clinical trials: Where do we stand and where can we go? Canadian Medical Association Journal. 2019;5(191):E128-E33.

- 45. Royal College of Physicians and Surgeons of Canada. Clinical Pharmacology and Toxicology Competencies: The Royal College of Physicians and Surgeons of Canada; 2021 [Available from: file:///C:/Users/vtelford/Downloads/clinical-pharmacology-toxicology-competencies-e%20(1).pdf.
- 46. Thabane L, Hopewell S, Lancaster GA, Bond CM, Coleman CL, Campbell MJ, et al. Methods and processes for development of a CONSORT extension for reporting pilot randomized controlled trials. Pilot Feasibility Stud. 2016;2:25.
- 47. Thabane L, Lancaster G. A guide to the reporting of protocols of pilot and feasibility trials. Pilot Feasibility Stud. 2019;5:37.
- 48. COACHeD RCT Capacity to Consent Questionnaire [Internet]. MacSphere. 2021. Available from: <a href="http://hdl.handle.net/11375/27712">http://hdl.handle.net/11375/27712</a>.
- 49. Shears M, Takaoka A, Rochwerg B, Bagshaw SM, Johnstone J, Holding A, et al. Assessing frailty in the intensive care unit: A reliability and validity study. J Crit Care. 2018;45:197-203.
- 50. Health Quality Ontario. Transitions between Hospital and Home: HQO; 2022 [Available from: <a href="https://www.hqontario.ca/Quality-Improvement/Quality-Improvement-in-Action/Health-Links/Health-Links-Resources/Transitions-between-Hospital-and-Home">https://www.hqontario.ca/Quality-Improvement/Quality-Improvement-in-Action/Health-Links/Health-Links-Resources/Transitions-between-Hospital-and-Home</a>.
- 51. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.
- 52. Fatima S, Holbrook A, Schulman S, Park S, Troyan S, Curnew G. Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. Thromb Res. 2016;145:143-8.
- 53. Holbrook AM PE, Troyan SM, Nikitovic M, Crowther MA. Personalized benefit-harm information influences patient decisions regarding warfarin. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique. 2013;20(3).
- 54. Hong C KS, Curnew G, Schulman S, Pullenayegum E, Holbrook A. Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique. 2013;20(3):e229-37.
- 55. Holbrook A, Labiris R, Goldsmith CH, Ota K, Harb S, Sebaldt RJ. Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. CMAJ. 2007;176(11):1583-7.
- 56. Lundahl B, Moleni T, Burke BL, Butters R, Tollefson D, Butler C, et al. Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials. Patient Educ Couns. 2013;93(2):157-68.
- 57. Rankin A CC, Ryan CI, Clyne B, Smith SM, Hughes CM. Core Outcome Set for Trials Aimed at Improving the Appropriateness of Polypharmacy in Older People in Primary Care. Journal of the American Geriatrics Society. 2018;66(6):1206-12.
- 58. Prinsen CA VS, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select outcome measurement instruments for outcomes included in a "Core Outcome Set" A Practical Guidline. Trials. 2016;17(1).
- 59. McDonald EG, Wu PE, Rashidi B, Wilson MG, Bortolussi-Courval E, Atique A, et al. The MedSafer Study-Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial. JAMA Intern Med. 2022;182(3):265-73.
- 60. Mangin D, Lamarche L, Agarwal G, Banh HL, Dore Brown N, Cassels A, et al. Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 2021;22(1):746.
- 61. Blum MR, Sallevelt B, Spinewine A, O'Mahony D, Moutzouri E, Feller M, et al. Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ. 2021;374:n1585.
- 62. O'Mahony D, Gudmundsson A, Soiza RL, Petrovic M, Jose Cruz-Jentoft A, Cherubini A, et al. Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR\* randomized controlled clinical trial. Age Ageing. 2020;49(4):605-14.
- 63. Riceckert A RD, Altiner A, Drewelow E, Esmail A, Flamm M, Hann M, Johansson T, Klaassen-Mielke R, Kunnamo I, Loffler C, Piccoliori G, Sommerauer C, Trampisch U, Vogele A, Woodham A, Sonnichsen A. Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. BMJ. 2020;369:m1822.
- 64. Vasilevskis E SAS, Hollingsworth E K, Shotwell S, Kripalani S, Mixon A, Simmons S. Deprescribing

- Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial. JAMA Intern Med. 2023.
- 65. Woo SA, Cragg A, Wickham ME, Peddie D, Balka E, Scheuermeyer F, et al. Methods for evaluating adverse drug event preventability in emergency department patients. BMC Med Res Methodol. 2018;18(1):160.
- 66. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324(6):377-84.
- 67. National Coordinating Council for Medication Error Reporting and Prevention. About Medication Errors: MERP: National Coordinating Council for Medication Error Reporting and Prevention; 2020 [Available from: <a href="https://www.nccmerp.org/about-medication-errors">https://www.nccmerp.org/about-medication-errors</a>.
- 68. Patient Safety Network. Patient Safety 101: Medication Errors and Adverse Drug Events Rockville, Maryland: Agency for Healthcare Research and Quality; 2019 [Available from: <a href="https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events">https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events</a>.
- 69. Holbrook A, Pullenayegum E, Thabane L, Troyan S, Foster G, Keshavjee K, et al. Shared electronic vascular risk decision support in primary care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) randomized trial. Arch Intern Med. 2011;171(19):1736-44.
- 70. American Society on Aging and American Society of Consultant Pharmacists Foundation. Medication Knowledge Assessment: Adult Medication; 2012 [Available from: http://adultmeducation.com/AssessmentTools 2.html.
- 71. Ontario HQ. Transitions between Hospital and Home: Care for People of All Ages: HQO; 2020 [Available from: <a href="https://www.hqontario.ca/Portals/0/documents/evidence/quality-standards/qs-transitions-between-hospital-and-home-quality-standard-en.pdf">https://www.hqontario.ca/Portals/0/documents/evidence/quality-standards/qs-transitions-between-hospital-and-home-quality-standard-en.pdf</a>.
- 72. Wenger NS, Roth CP, Shekelle P, Investigators A. Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set. J Am Geriatr Soc. 2007;55 Suppl 2:S247-52.
- 73. Euroqol. EQ-5D Instruments: Euroqol; 2018 [Available from: <a href="https://euroqol.org/eq-5d-instruments/">https://euroqol.org/eq-5d-instruments/</a>.
- 74. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-36.
- 75. Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, et al. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98-105.
- 76. Tseng HM, Lee CH, Chen YJ, Hsu HH, Huang LY, Huang JL. Developing a measure of medication-related quality of life for people with polypharmacy. Qual Life Res. 2016;25(5):1295-302.
- 77. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: version 1.0. Trials. 2017;18(Suppl 3):280.
- 78. Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, et al. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT AF Registry. J Am Heart Assoc. 2019;8(9):e011205.
- 79. COACHED RCT Additional Files 2021 (CCCQ, OAC Knowledge Test, Patient/Caregiver Study Satisfaction Survey) [Internet]. MacSphere, McMaster University. 2021. Available from: http://hdl.handle.net/11375/27213.
- 80. Carrasquillo O. Health Care Utilization. Encyclopedia of Behavioral Medicine. Gellman MD, Turner JR ed. New York: Springer; 2013. p. 909-10.
- 81. Canadian Agency for Drug and Technogolies in Health (CADTH). Canadian Agency for Drug and Technogolies in Health [Internet] Canada: Canadian Journal of Health Technologies; 2021 [Available from: <a href="https://www.cadth.ca/">https://www.cadth.ca/</a>.
- 82. CADTH. Guidelines for the Economic Evaluation of Health Technologies: Canada. Ottawa, ON: CADTH; 2017.
- 83. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161-72.
- 84. Statulator. Statulator An Online Statistical Calculator (Sample Size Calculator for Comparing Two Independent Means): online; 2014 [Available from: http://statulator.com/SampleSize/ss2M.html.
- 85. LJ W. The Adaptive Biased Coin Design for Sequential Experiments. The Annals of Statistics.

- 1978;6(1):92-100.
- 86. Markaaryan T RW. Exact properties of Efron's biased coin randomization procedure. Ann Statist. 2010;38(3):1546-67.
- 87. Soares JF JWC. Some restricted randomization rules in sequential designs. Communications in Statistics. 1983;12(17):2017-34.
- 88. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
- 89. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
- 90. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016;2:64.
- 91. Holbrook A VK, Yoo L, Troyan S, Schulman S, Douketis J, Thabane L, Giilck S, Koubaesh Y, Hyland S, Keshavjee K, Ho J, Tarride J-E, Ahemd A, Talman M, Leonard B, Ahemd K, Refai M, Siegal D. Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): Protocol for a Pilot Randomised Controlled Trial. Pilot Feasibility Stud. 2022;8(166).
- 92. Ross MCSB, Wu PE, Atique Md Candidate A, Papillon-Ferland L, Tamblyn R, Lee TC, et al. Adverse Drug Events in Older Adults: Review of Adjudication Methods in Deprescribing Studies. J Am Geriatr Soc. 2020;68(7):1594-602.

Figure 1. IMPROVE-IT HRM RCT Flow Diagram




Figure 2. IMPROVE-IT HRM Clinical Approach




Table 1. IMPROVE-IT HRM OUTCOMES<sup>29, 30, 57, 59, 60, 65, 68, 91, 92</sup>

	Outcome
Feasibility	1. Participant recruitment rates
	2. Participant retention rate
	3. Trial resource utilization, costs
	4. Recommendation acceptance rates by MRP team
	5. Recommendation acceptance rates by patient
	6. Recommendation adherence rates by patient
	7. CPICS consultation volume capacity
	8. Potential to intervene entirely virtually (online)
Clinical	1. Medication Management Outcomes
	a) # drug therapy problems improved
	b) # High Risk medication problems improved
	c) # PIMs tapered or discontinued (using APEQ)
	d) # medications per patient end-study versus baseline
	2. Adverse drug events including adverse drug withdrawal event
	3. Medication Errors, including preventability
	4. Patient Problems with Medications Questionnaire (includes general adherence)
	5. Coordination and continuity of care
	6. Patient Quality of Life (EQ-5D-5L and Medication-related QOL)
	7. Patient Knowledge of Medications
	8. Satisfaction with Care (Patients and Providers)
	9. Health Resource Utilization, including Clinical events of death, ED visits,
	hospitalization or unplanned physician visits; medication costs, to estimate cost - effectiveness

<sup>\*</sup> An Adverse drug event (ADE) is defined as "Harm caused by exposure to a drug" whereas an adverse drug reaction (ADR) is a subset of these events, where harm is caused by a drug under appropriate use (i.e. at usual doses) – adjudicated using Leape and Bates scale: 6- definitely due to medication, 5- probably due to medication, 4- possibly due to medication, 3- possibly due to disease, 2- probably due to disease, 1- definitely due to disease (5 and 6 considered ADE). Medication Errors have been defined as an error (of commission or omission) at any step along the pathway that begins with prescribing and ends with the patient taking the medication. Medication.

**Table 2. IMPROVE-IT HRM Study Outcomes and Measures** 

	Outcomes*	Criteria for success	<b>Outcome Measure</b>	Method of Analysis	When Assessed
A. Feasibility		200/ 0.1			
A1. Primary feasibility outcomes	A1.1 Participant recruitment rates	≥ 30% of those eligible will be considered success	Percentage recruited and rate of recruitment (of those screened, of those eligible and of those approached).	Count of percentages over time	Baseline
	A1.2 Participant retention rate	≥ 90% is considered success	Primary: Percentage of those recruited (eligible and signed informed consent) who were alive at end of study**	Count of percentages over time	End of study
	A1.3 Intervention Adherence	≥ 90% is considered success	Percentage of those recruited who completed each phase of the study (baseline, virtual visits, end of study)	Count of percentages over time	End of study
	A1.4 Study Resource Utilization	< \$1500 per patient recruited and completing the study	Study costs per patient recruited to end-follow-up	Cost of personnel, supplies, travel, etc. to run the study	End of study
A2. Secondary feasibility outcomes	A2.1 CPICS Recommendation Acceptance – Primary Team	≥ 50% medication recommendations	% CPICS recommendations per patient accepted (continued or implemented)	Count of percentages over time, Descriptive	End of study
	A2.2 CPICS Recommendation Acceptance – Patients	≥ 50% medication recommendations	% CPICS recommendations per patient that were followed by patient	Count of percentages over time, Descriptive	End of study

	A2.3 CPICS Recommendation Adherence – Patients	≥ 90% is considered success	% of intervention patients who follow CPICS recommendations throughout the study (virtual visits, end of study)	Count of percentages over time, Descriptive	Virtual Visits, End of Study
	A2.4 CPICS Consultation Volume Capacity	Number of eligible patients available to approach per week is > 3 per day	Volume of eligible patients available to approach per week	Count of percentages over time	Baseline
	A2.5 Potential to intervene entirely virtually	≥ 90% patients can be managed through follow-up entirely by virtual care platform	Number (%) patients entering follow-up who do not require an unscheduled in person visit Number of follow-up visits conducted using secure videoconference platform	Count of percentages over time, Descriptive Count of rates and percentages over time	End of study
B. Clinical Outcomes		F			
B1. Primary clinical outcomes	B1.1 Drug Therapy Problems Improved	Intervention group will have more improved drug therapy problems compared to control group (e.g. dose adjusted, discontinued, interacting drugs removed)	Percentage of identified baseline drug therapy problems that have been improved by end of study	Count of percentages by end of study	End of study
B2 Secondary	B2.1 Medication	Intervention will	# medications adjusted	T-tests	Baseline, Virtual

B2.2 Adverse Drug Events	Intervention will have lower event rates than control	throughout study; # High Risk medications remaining adjusted as per CPT recommendations end-study; # PIMs tapered or discontinued; # medications per patient end-study versus baseline  Event rate counts from end of study interviews using Leape and Bates scale	T-tests	End of study
B2.3 Coordination and continuity of care	Intervention will have higher ratings than control	Coordination and Continuity of Care Questionnaire	T-tests	End of study
B2.4 Patient quality of life	Intervention will improve more than control	EQ5D-5L and MedQOL - difference in mean change scores at the end of the study.	T-tests (scored in SAS)	Baseline and end of study
B2.5 Medication Knowledge – patient	Intervention will have higher scores than control	Medication Knowledge Assessment Form	T-tests	Baseline and end of study
B2.6 Patient Satisfaction with Care	Intervention will have higher scores than control	Patient Satisfaction Questionnaire	Descriptive analysis	End of study
B2.7 Provider Satisfaction with Care	Intervention will have higher scores than control	Physician, pharmacist Study Satisfaction Questionnaire	Descriptive analysis	End of study
B2.9 Patient Problems with Medications	Intervention will have fewer medication problems than control	COMPETE Medication Problems Questionnaire	T-tests	End of study

B2.	.10 Medication Errors	Intervention will have fever medication errors	NCC-MERP definition	T-tests	End of study
effe	.11 Cost- ectiveness/Resource lization	Intervention will be cost-effective compared to control using a threshold of \$50,000 per QALY.	Cost per adverse drug events avoided and cost per quality- adjusted life-years (QALYs)	Economic analysis	Based on EQ-5D-5L at baseline and 3- month follow-up, and adverse events at 3-month follow-
					up

<sup>\*\*</sup>Include patients who are alive and those we were able to follow throughout the study, but may not complete the 3-month follow-up

Appendix 1. IMPROVE-IT HRM High-Risk Medications  $^{27,\,28}$ 

Medication Families	Medications	ATC Codes
1. Anti-thrombotics	Warfarin	B01AA03
	Acenocoumarol	B01AA07
	Heparin	B01AB01
	Enoxaparin	B01AB05
	Nadroparin	B01AB06
	Tinzaparin	B01AB10
	Argatroban	B01AE03
	Bivalirudin	B01AE06
	Dabigatran etexilate	B01AE07
	Rivaroxaban	B01AF01
	Apixaban	B01AF02
	Edoxaban	B01AF03
	Fondaparinux	B01AX05
2. Analgesics	-	
	Morphine	N02AA01
2.1. Opioids	Hydromorphone	N02AA03
	Oxycodone	N02AA05
	Fentanyl	N02AB03
	Buprenorphine	N02AE01
	Butorphanol	N02AF01
	Nalbuphine	N02AF02
	Tramadol	N02AX02
	Tapentadol	N02AX06
	Codeine	R05DA04
	Hydrocodone	R05DA03
	Methadone	N07BC02
	Diamorphine	N07BC06
	Oxycodone and naloxone	N02AA55
	Codeine, combinations with psycholeptics	N02AA79
	Oxycodone and paracetamol	N02AJ17
	Oxycodone and acetylsalicylic acid	N02AJ18

59 13 06 03 01 02 04 06
06 03 01 02 04 06
03 01 02 04 06
01 02 04 06
02 04 06
04 06
06
07
08
09
10
201
02
07
08
12
01
01
04
02
12
)5
01
)2
)9
)2
)4
01
03
04
05
01
02

Ceftriaxone	J01DD04
Cefixime	J01DD08
Cefepime	J01DE01
Aztreonam	J01DF01
Meropenem	J01DH02
Ertapenem	J01DH03
Ceftobiprole medocaril	J01DI01
Trimethoprim	J01EA01
Sulfamethizole	J01EB02
Sulfapyridine	J01EB04
Sulfamethoxazole and trimethoprim	J01EE01
Sulfadiazine	J01EC02
Erythromycin	J01FA01
Spiramycin	J01FA02
Clarithromycin	J01FA09
Azithromycin	J01FA10
Clindamycin	J01FF01
Streptomycin	J01GA01
Tobramycin	J01GB01
Gentamicin	J01GB03
Amikacin	J01GB06
Ciprofloxacin	J01MA02
Norfloxacin	J01MA06
Levofloxacin	J01MA12
Moxifloxacin	J01MA14
Vancomycin	J01XA01
Telavancin	J01XA03
Dalbavancin	J01XA04
Colistin	J01XB01
Polymyxin B	J01XB02
Metronidazole	J01XD01
Nitrofurantoin	J01XE01
Fosfomycin	J01XX01
Spectinomycin	J01XX04
Methenamine	J01XX05
•	

Linezolid         J01XX08           Daptomycin         J01XX09           Bacitracin         J01XX10           Tedizolid         J01XX11           Ceftolozane and beta-lactamase inhibitor         J01DI54           Imipenem and cilastatin         J01DH51           Lefamulin         J01XX12           Amphotericin B         J02AA01           Ketoconazole         J02AR02           Fluconazole         J02AC01           Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC03           Posaconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04AR02           Acyclovir         J05AB06           Famciclovir         J05AB06           Famciclovir         J05AB06           Valganciclovir         J05AB12           Valganciclovir <th></th> <th></th>		
Bacitracin         J01XX10           Tedizolid         J01XX11           Ceftolozane and beta-lactamase inhibitor         J01DI54           Imipenem and cilastatin         J01DH51           Lefamulin         J01XX12           Amphotericin B         J02AA01           Ketoconazole         J02AB02           Fluconazole         J02AC01           Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC04           Isavuconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB02           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB01           Valaciclovir         J05AB04           Valganciclovir         J05AB12           Valganciclovir         J05AB16           Foscarnet         J05AB03           Fosamprenavi	Linezolid	J01XX08
Tedizolid Ceftolozane and beta-lactamase inhibitor J01DI54 Imipenem and cilastatin J01DH51 Lefamulin J01XX12 Amphotericin B J02AA01 Ketoconazole Fluconazole J02AC02 Voriconazole J02AC02 Voriconazole J02AC03 Posaconazole J02AC04 Isavuconazole J02AC05 Caspofungin J02AX04 Micafungin J02AX05 Anidulafungin J02AX06 Rifampicin J04AB02 Rifabutin J04AB04 Isoniazid J04AC01 Pyrazinamide J04AK01 Ethambutol J04AK02 Dapsone J04BA02 Acyclovir J05AB01 Ganciclovir J05AB06 Famciclovir J05AB11 Cidofovir J05AB12 Valganciclovir J05AB16 Foscarnet J05AE03 Fosamprenavir J05AE03 Fosamprenavir J05AE03 Fosamprenavir J05AE08	Daptomycin	J01XX09
Ceftolozane and beta-lactamase inhibitorJ01DI54Imipenem and cilastatinJ01DH51LefamulinJ01XX12Amphotericin BJ02AA01KetoconazoleJ02AB02FluconazoleJ02AC01ItraconazoleJ02AC02VoriconazoleJ02AC03PosaconazoleJ02AC04IsavuconazoleJ02AC05CaspofunginJ02AX04MicafunginJ02AX05AnidulafunginJ02AX06RifampicinJ04AB02RifabutinJ04AB04IsoniazidJ04AC01PyrazinamideJ04AK01EthambutolJ04AK02DapsoneJ04BA02AcyclovirJ05AB01GanciclovirJ05AB06FamciclovirJ05AB09ValaciclovirJ05AB11CidofovirJ05AB12ValganciclovirJ05AB14RemdesivirJ05AB16FoscarnetJ05AB01RitonavirJ05AE03FosamprenavirJ05AE03AtazanavirJ05AE08	Bacitracin	J01XX10
Imipenem and cilastatin         J01DH51           Lefamulin         J01XX12           Amphotericin B         J02AA01           Ketoconazole         J02AB02           Fluconazole         J02AC01           Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC04           Isavuconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB02           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AB03           Fosamprenavir         J05AE03           Atazanavir         J05AE08	Tedizolid	J01XX11
Lefamulin         J01XX12           Amphotericin B         J02AA01           Ketoconazole         J02AB02           Fluconazole         J02AC01           Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB1           Cidofovir         J05AB1           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AB03           Fosamprenavir         J05AE03           Atazanavir         J05AE08	Ceftolozane and beta-lactamase inhibitor	J01DI54
Amphotericin B         J02AA01           Ketoconazole         J02AB02           Fluconazole         J02AC01           Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC04           Isavuconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB01           Famciclovir         J05AB06           Famciclovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AB03           Fosamprenavir         J05AE03           Atazanavir         J05AE08	Imipenem and cilastatin	J01DH51
Ketoconazole         J02AB02           Fluconazole         J02AC01           Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC05           Lisavuconazole         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB01           Valaciclovir         J05AB09           Valaciclovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AB03           Fosamprenavir         J05AE03           Fosamprenavir         J05AE08	Lefamulin	J01XX12
Fluconazole         J02AC01           Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC05           Isavuconazole         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04AR02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AB03           Fosamprenavir         J05AE03           Fosamprenavir         J05AE08	Amphotericin B	J02AA01
Itraconazole         J02AC02           Voriconazole         J02AC03           Posaconazole         J02AC05           Isavuconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB02           Rifabutin         J04AK01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J05AB01           Ganciclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AB01           Ritonavir         J05AE03           Fosamprenavir         J05AE08	Ketoconazole	J02AB02
Voriconazole         J02AC03           Posaconazole         J02AC04           Isavuconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB06           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE08	Fluconazole	J02AC01
Posaconazole         J02AC04           Isavuconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J05AB01           Ganciclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE08	Itraconazole	J02AC02
Isavuconazole         J02AC05           Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB10           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE08	Voriconazole	J02AC03
Caspofungin         J02AX04           Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Posaconazole	J02AC04
Micafungin         J02AX05           Anidulafungin         J02AX06           Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J05AB01           Ganciclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Isavuconazole	J02AC05
Anidulafungin  Rifampicin  J04AB02  Rifabutin  J04AB04  Isoniazid  J04AC01  Pyrazinamide  Ethambutol  Dapsone  J04BA02  Acyclovir  J05AB01  Ganciclovir  J05AB06  Famciclovir  J05AB11  Cidofovir  J05AB12  Valganciclovir  J05AB14  Remdesivir  J05AB06  Foscarnet  J05AB06  Foscarnet  J05AB06  Foscarnet  J05AB16  Foscarnet  J05AB06  Foscarnet  J05AB06  J05AB16  Foscarnet  J05AB06  J05AB16  Foscarnet  J05AB06  Foscarnet  J05AB06  J05AB06  J05AB16  Foscarnet  J05AB06	Caspofungin	J02AX04
Rifampicin         J04AB02           Rifabutin         J04AB04           Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Micafungin	J02AX05
Rifabutin J04AB04 Isoniazid J04AC01 Pyrazinamide J04AK01 Ethambutol J04AK02 Dapsone J04BA02 Acyclovir J05AB01 Ganciclovir J05AB06 Famciclovir J05AB11 Cidofovir J05AB11 Cidofovir J05AB12 Valganciclovir J05AB14 Remdesivir J05AB16 Foscarnet J05AD01 Ritonavir J05AE03 Fosamprenavir J05AE07 Atazanavir J05AE08	Anidulafungin	J02AX06
Isoniazid         J04AC01           Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Rifampicin	J04AB02
Pyrazinamide         J04AK01           Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Rifabutin	J04AB04
Ethambutol         J04AK02           Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Isoniazid	J04AC01
Dapsone         J04BA02           Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Pyrazinamide	J04AK01
Acyclovir         J05AB01           Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Ethambutol	J04AK02
Ganciclovir         J05AB06           Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Dapsone	J04BA02
Famciclovir         J05AB09           Valaciclovir         J05AB11           Cidofovir         J05AB12           Valganciclovir         J05AB14           Remdesivir         J05AB16           Foscarnet         J05AD01           Ritonavir         J05AE03           Fosamprenavir         J05AE07           Atazanavir         J05AE08	Acyclovir	J05AB01
ValaciclovirJ05AB11CidofovirJ05AB12ValganciclovirJ05AB14RemdesivirJ05AB16FoscarnetJ05AD01RitonavirJ05AE03FosamprenavirJ05AE07AtazanavirJ05AE08	Ganciclovir	J05AB06
CidofovirJ05AB12ValganciclovirJ05AB14RemdesivirJ05AB16FoscarnetJ05AD01RitonavirJ05AE03FosamprenavirJ05AE07AtazanavirJ05AE08	Famciclovir	J05AB09
ValganciclovirJ05AB14RemdesivirJ05AB16FoscarnetJ05AD01RitonavirJ05AE03FosamprenavirJ05AE07AtazanavirJ05AE08	Valaciclovir	J05AB11
RemdesivirJ05AB16FoscarnetJ05AD01RitonavirJ05AE03FosamprenavirJ05AE07AtazanavirJ05AE08	Cidofovir	J05AB12
Foscarnet J05AD01 Ritonavir J05AE03 Fosamprenavir J05AE07 Atazanavir J05AE08	Valganciclovir	J05AB14
Ritonavir J05AE03 Fosamprenavir J05AE07 Atazanavir J05AE08	Remdesivir	J05AB16
Fosamprenavir J05AE07 Atazanavir J05AE08	Foscarnet	J05AD01
Atazanavir J05AE08	Ritonavir	J05AE03
	Fosamprenavir	J05AE07
Tipranavir J05AE09	Atazanavir	J05AE08
	Tipranavir	J05AE09

Darunavir	J05AE10
Nirmatrelvir and ritonavir	J05AE30
Zidovudine	J05AF01
Lamivudine	J05AF05
Abacavir	J05AF06
Tenofovir disoproxil	J05AF07
Adefovir dipivoxil	J05AF08
Entecavir	J05AF10
Tenofovir alafenamide	J05AF13
Nevirapine	J05AG01
Efavirenz	J05AG03
Etravirine	J05AG04
Rilpivirine	J05AG05
Doravirine	J05AG06
Zanamivir	J05AH01
Oseltamivir	J05AH02
Raltegravir	J05AJ01
Dolutegravir	J05AJ03
Cabotegravir	J05AJ04
Ribavirin	J05AP01
Sofosbuvir	J05AP08
Sofosbuvir and ledipasvir	J05AP51
Sofosbuvir and velpatasvir	J05AP55
Sofosbuvir, velpatasvir and voxilaprevir	J05AP56
Glecaprevir and pibrentasvir	J05AP57
Zidovudine and lamivudine	J05AR01
Lamivudine and abacavir	J05AR02
Tenofovir disoproxil and emtricitabine	J05AR03
Zidovudine, lamivudine and nevirapine	J05AR05
Emtricitabine, tenofovir disoproxil and	J05AR06
efavirenz	
Emtricitabine, tenofovir disoproxil and	J05AR08
rilpivirine	
Emtricitabine, tenofovir disoproxil,	J05AR09
elvitegravir and cobicistat	

	Lopinavir and ritonavir	J05AR10
	Lamivudine, abacavir and dolutegravir	J05AR13
	Darunavir and cobicistat	J05AR14
	Emtricitabine and tenofovir alafenamide	J05AR17
	Emtricitabine, tenofovir alafenamide,	J05AR18
	elvitegravir and cobicistat	
	Emtricitabine, tenofovir alafenamide and	J05AR19
	rilpivirine	
	Emtricitabine, tenofovir alafenamide and	J05AR20
	bictegravir	
	Dolutegravir and rilpivirine	J05AR21
	Emtricitabine, tenofovir alafenamide,	J05AR22
	darunavir and cobicistat	
	Lamivudine, tenofovir disoproxil and	J05AR24
	doravirine	
	Lamivudine and dolutegravir	J05AR25
	Inosine pranobex	J05AX05
	Enfuvirtide	J05AX07
	Maraviroc	J05AX09
	Maribavir	J05AX10
	Letermovir	J05AX18
	Tecovirimat	J05AX24
	Baloxavir marboxil	J05AX25
	Fostemsavir	J05AX29
	Lenacapavir	J05AX31
4. Antineoplastics	Cyclophosphamide	L01AA01
	Chlorambucil	L01AA02
	Melphalan	L01AA03
	Chlormethine	L01AA05
	Ifosfamide	L01AA06
	Bendamustine	L01AA09
	Busulfan	L01AB01
	Treosulfan	L01AB02
	Thiotepa	L01AC01
	Carmustine	L01AD01

Lomustine	L01AD02
Temozolomide	L01AX03
Dacarbazine	L01AX04
Methotrexate	L01BA01
Raltitrexed	L01BA03
Pemetrexed	L01BA04
Pralatrexate	L01BA05
Mercaptopurine	L01BB02
Tioguanine	L01BB03
Cladribine	L01BB04
Fludarabine	L01BB05
Clofarabine	L01BB06
Nelarabine	L01BB07
Cytarabine	L01BC01
Fluorouracil	L01BC02
Gemcitabine	L01BC05
Capecitabine	L01BC06
Azacitidine	L01BC07
Decitabine	L01BC08
Vinblastine	L01CA01
Vincristine	L01CA02
Vindesine	L01CA03
Vinorelbine	L01CA04
Paclitaxel	L01CD01
Docetaxel	L01CD02
Cabazitaxel	L01CD04
Topotecan	L01CE01
Irinotecan	L01CE02
Trabectedin	L01CX01
Dactinomycin	L01DA01
Doxorubicin	L01DB01
Daunorubicin	L01DB02
Epirubicin	L01DB03
Idarubicin	L01DB06
Mitoxantrone	L01DB07

Bleomycin	L01DC01
Mitomycin	L01DC03
Imatinib	L01EA01
Dasatinib	L01EA02
Nilotinib	L01EA03
Bosutinib	L01EA04
Ponatinib	L01EA05
Asciminib	L01EA06
Gefitinib	L01EB01
Erlotinib	L01EB02
Afatinib	L01EB03
Osimertinib	L01EB04
Dacomitinib	L01EB07
Vemurafenib	L01EC01
Dabrafenib	L01EC02
Encorafenib	L01EC03
Crizotinib	L01ED01
Ceritinib	L01ED02
Alectinib	L01ED03
Brigatinib	L01ED04
Lorlatinib	L01ED05
Trametinib	L01EE01
Cobimetinib	L01EE02
Binimetinib	L01EE03
Selumetinib	L01EE04
Palbociclib	L01EF01
Ribociclib	L01EF02
Abemaciclib	L01EF03
Temsirolimus	L01EG01
Everolimus	L01EG02
Lapatinib	L01EH01
Neratinib	L01EH02
Tucatinib	L01EH03
Ruxolitinib	L01EJ01
Fedratinib	L01EJ02

Axitinib	L01EK01
Ibrutinib	L01EL01
Acalabrutinib	L01EL02
Zanubrutinib	L01EL02
Idelalisib	
	L01EM01
Alpelisib Erdafitinib	L01EM03
	L01EN01
Pemigatinib	L01EN02
Infigratinib	L01EN03
Sunitinib	L01EX01
Sorafenib	L01EX02
Pazopanib	L01EX03
Vandetanib	L01EX04
Regorafenib	L01EX05
Cabozantinib	L01EX07
Lenvatinib	L01EX08
Nintedanib	L01EX09
Midostaurin	L01EX10
Larotrectinib	L01EX12
Gilteritinib	L01EX13
Entrectinib	L01EX14
Capmatinib	L01EX17
Ripretinib	L01EX19
Tepotinib	L01EX21
Selpercatinib	L01EX22
Pralsetinib	L01EX23
Rituximab	L01FA01
Ofatumumab	L01FA02
Obinutuzumab	L01FA03
Inotuzumab ozogamicin	L01FB01
Daratumumab	L01FC01
Isatuximab	L01FC02
Trastuzumab	L01FD01
Pertuzumab	L01FD02
Trastuzumab emtansine	L01FD03

Trastuzumab deruxtecan  Cetuximab  Lo1FE01  Panitumumab  Lo1FE02  Necitumumab  Lo1FF01  Pembrolizumab  Lo1FF02  Durvalumab  Lo1FF02  Durvalumab  Lo1FF03  Avelumab  Lo1FF03  Avelumab  Lo1FF04  Atezolizumab  Lo1FF05  Cemiplimab  Lo1FF06  Dostarlimab  Lo1FF07  Bevacizumab  Lo1FG01  Ramucirumab  Lo1FG02  Gemtuzumab ozogamicin  Lo1FX02  Ipilimumab  Lo1FX04  Brentuximab vedotin  Lo1FX05  Dinutuximab  Lo1FX06  Blinatumomab  Lo1FX06  Blinatumomab  Lo1FX07  Elotuzumab  Mogamulizumab  Lo1FX08  Mogamulizumab  Lo1FX09  Tafasitamab  Lo1FX12  Enfortumab vedotin  Lo1FX12  Enfortumab vedotin  Lo1FX13  Polatuzumab vedotin  Lo1FX14  Sacituzumab govitecan  Lo1FX17  Amivantamab  Lo1FX18  Cisplatin  Lo1XA01  Carboplatin  Lo1XA03  Procarbazine  Lo1XD01  Methyl aminolevulinate  Lo1XD01  Methyl aminolevulinate  Lo1XG01  Carfilzomib  Lo1XG01  Carfilzomib  Lo1XG02		
PanitumumabL01FE02NecitumumabL01FE03NivolumabL01FF01PembrolizumabL01FF02DurvalumabL01FF03AvelumabL01FF04AtezolizumabL01FF05CemiplimabL01FF06DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX12Polatuzumab vedotinL01FX13Polatuzumab govitecanL01FX14Sacituzumab govitecanL01FX18CisplatinL01FX18CisplatinL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Trastuzumab deruxtecan	L01FD04
NecitumumabL01FE03NivolumabL01FF01PembrolizumabL01FF02DurvalumabL01FF03AvelumabL01FF04AtezolizumabL01FF05CemiplimabL01FF06DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XF01BortezomibL01XG01	Cetuximab	L01FE01
NivolumabL01FF01PembrolizumabL01FF02DurvalumabL01FF03AvelumabL01FF04AtezolizumabL01FF05CemiplimabL01FF06DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinic acidL01XD03Aminolevulinic acidL01XF01BortezomibL01XG01	Panitumumab	L01FE02
PembrolizumabL01FF02DurvalumabL01FF03AvelumabL01FF04AtezolizumabL01FF05CemiplimabL01FF06DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Necitumumab	L01FE03
DurvalumabL01FF03AvelumabL01FF04AtezolizumabL01FF05CemiplimabL01FF06DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Nivolumab	L01FF01
Avelumab	Pembrolizumab	L01FF02
AtezolizumabL01FF05CemiplimabL01FF06DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Durvalumab	L01FF03
CemiplimabL01FF06DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Avelumab	L01FF04
DostarlimabL01FF07BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XG01	Atezolizumab	L01FF05
BevacizumabL01FG01RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Cemiplimab	L01FF06
RamucirumabL01FG02Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XF01BortezomibL01XG01	Dostarlimab	L01FF07
Gemtuzumab ozogamicinL01FX02IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XF01BortezomibL01XG01	Bevacizumab	L01FG01
IpilimumabL01FX04Brentuximab vedotinL01FX05DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XF01BortezomibL01XG01	Ramucirumab	L01FG02
Brentuximab vedotin Dinutuximab Dinutuximab Dinutuximab Dinutuximab Dinutuximab Dinutuximab Dinutuximab Dinutuximab L01FX07 Elotuzumab L01FX08 Mogamulizumab L01FX09 Tafasitamab L01FX12 Enfortumab vedotin Dinutuximab vedotin L01FX13 Polatuzumab vedotin L01FX14 Sacituzumab govitecan L01FX17 Amivantamab L01FX18 Cisplatin L01XA01 Carboplatin L01XA02 Oxaliplatin Doxaliplatin Porfimer sodium L01XD01 Methyl aminolevulinate L01XD03 Aminolevulinic acid L01XF01 Bortezomib L01XG01	Gemtuzumab ozogamicin	L01FX02
DinutuximabL01FX06BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Ipilimumab	L01FX04
BlinatumomabL01FX07ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Brentuximab vedotin	L01FX05
ElotuzumabL01FX08MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Dinutuximab	L01FX06
MogamulizumabL01FX09TafasitamabL01FX12Enfortumab vedotinL01FX13Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XG01BortezomibL01XG01	Blinatumomab	L01FX07
Tafasitamab         L01FX12           Enfortumab vedotin         L01FX13           Polatuzumab vedotin         L01FX14           Sacituzumab govitecan         L01FX17           Amivantamab         L01FX18           Cisplatin         L01XA01           Carboplatin         L01XA02           Oxaliplatin         L01XA03           Procarbazine         L01XB01           Porfimer sodium         L01XD01           Methyl aminolevulinate         L01XD03           Aminolevulinic acid         L01XD04           Tretinoin         L01XF01           Bortezomib         L01XG01	Elotuzumab	L01FX08
Enfortumab vedotin Polatuzumab vedotin L01FX14 Sacituzumab govitecan L01FX17 Amivantamab L01FX18 Cisplatin L01XA01 Carboplatin L01XA02 Oxaliplatin L01XA03 Procarbazine L01XB01 Porfimer sodium L01XD01 Methyl aminolevulinate L01XD03 Aminolevulinic acid L01XF01 Bortezomib L01XG01	Mogamulizumab	L01FX09
Polatuzumab vedotinL01FX14Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Tafasitamab	L01FX12
Sacituzumab govitecanL01FX17AmivantamabL01FX18CisplatinL01XA01CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Enfortumab vedotin	L01FX13
Amivantamab         L01FX18           Cisplatin         L01XA01           Carboplatin         L01XA02           Oxaliplatin         L01XA03           Procarbazine         L01XB01           Porfimer sodium         L01XD01           Methyl aminolevulinate         L01XD03           Aminolevulinic acid         L01XD04           Tretinoin         L01XF01           Bortezomib         L01XG01	Polatuzumab vedotin	L01FX14
Cisplatin         L01XA01           Carboplatin         L01XA02           Oxaliplatin         L01XA03           Procarbazine         L01XB01           Porfimer sodium         L01XD01           Methyl aminolevulinate         L01XD03           Aminolevulinic acid         L01XD04           Tretinoin         L01XF01           Bortezomib         L01XG01	Sacituzumab govitecan	L01FX17
CarboplatinL01XA02OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Amivantamab	L01FX18
OxaliplatinL01XA03ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Cisplatin	L01XA01
ProcarbazineL01XB01Porfimer sodiumL01XD01Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Carboplatin	L01XA02
Porfimer sodium L01XD01  Methyl aminolevulinate L01XD03  Aminolevulinic acid L01XD04  Tretinoin L01XF01  Bortezomib L01XG01	Oxaliplatin	L01XA03
Methyl aminolevulinateL01XD03Aminolevulinic acidL01XD04TretinoinL01XF01BortezomibL01XG01	Procarbazine	L01XB01
Aminolevulinic acid         L01XD04           Tretinoin         L01XF01           Bortezomib         L01XG01	Porfimer sodium	L01XD01
Tretinoin L01XF01 Bortezomib L01XG01	Methyl aminolevulinate	L01XD03
Bortezomib L01XG01	Aminolevulinic acid	L01XD04
Bortezomib L01XG01	Tretinoin	L01XF01
Carfilzomib L01XG02	Bortezomib	L01XG01
	Carfilzomib	L01XG02

	Ixazomib	L01XG03
	Vorinostat	L01XH01
	Romidepsin	L01XH02
	Vismodegib	L01XJ01
	Sonidegib	L01XJ02
	Glasdegib	L01XJ03
	Olaparib	L01XK01
	Niraparib	L01XK02
	Talazoparib	L01XK04
	Axicabtagene ciloleucel	L01XL03
	Tisagenlecleucel	L01XL04
	Brexucabtagene autoleucel	L01XL06
	Idecabtagene vicleucel	L01XL07
	Amsacrine	L01XX01
	Asparaginase	L01XX02
	Altretamine	L01XX03
	Hydroxycarbamide	L01XX05
	Pentostatin	L01XX08
	Estramustine	L01XX11
	Mitotane	L01XX23
	Pegaspargase	L01XX24
	Arsenic trioxide	L01XX27
	Anagrelide	L01XX35
	Eribulin	L01XX41
	Aflibercept	L01XX44
	Venetoclax	L01XX52
	Enasidenib	L01XX59
	Selinexor	L01XX66
	Lurbinectedin	L01XX69
	Sotorasib	L01XX73
	Belzutifan	L01XX74
	Tebentafusp	L01XX75
5. Glucose	Glibenclamide	A10BB01
lowering/hypoglycemics	Chlorpropamide	A10BB02
	Tolbutamide	A10BB03

	Gliclazide	A10BB09
	Glimepiride	A10BB12
	Acarbose	A10BF01
	Rosiglitazone	A10BG02
	Pioglitazone	A10BG03
	Sitagliptin	A10BH01
	Saxagliptin	A10BH03
	Alogliptin	A10BH04
	Linagliptin	A10BH05
	Liraglutide	A10BJ02
	Lixisenatide	A10BJ03
	Dulaglutide	A10BJ05
	Semaglutide	A10BJ06
	Dapagliflozin	A10BK01
	Canagliflozin	A10BK02
	Empagliflozin	A10BK03
	Repaglinide	A10BX02
	Tirzepatide	A10BX16
	Insulin human	A10AB01
	Insulin pork	A10AB03
	Insulin lispro	A10AB04
	Insulin aspart	A10AB05
	Insulin glulisine	A10AB06
	Insulin human (intermediate acting)	A10AC01
	Insulin pork (intermediate acting)	A10AC03
	Insulin human (long acting)	A10AD01
	Insulin lispro (long acting)	A10AD04
	Insulin aspart (long acting)	A10AD05
6. Hormone therapy		
6.1 Postmenopausal estrogen	Estradiol	G03CA03
	Estrone	G03CA07
	Dienestrol	G03CB01
	Tibolone	G03CX01
6.2. Androgens for menopause	Methyltestosterone	G03BA02
	Testosterone	G03BA03

7. Cardiac Medications		
7.1. Diuretics	Hydrochlorothiazide	C03AA03
	Chlorthalidone	C03BA04
	Metolazone	C03BA08
	Indapamide	C03BA11
	Furosemide	C03CA01
	Bumetanide	C03CA02
	Etacrynic acid	C03CC01
	Spironolactone	C03DA01
	Eplerenone	C03DA04
	Amiloride	C03DB01
	Tolvaptan	C03XA01
7.2. Digoxin	Digoxin	C01AA05
7.3. Amiodarone	Amiodarone	C01BD01
8. Sedatives and hypnotics		
8.2. BZRAs	Flurazepam	N05CD01
	Nitrazepam	N05CD02
	Triazolam	N05CD05
	Temazepam	N05CD07
	Midazolam	N05CD08
	Zopiclone	N05CF01
	Zolpidem	N05CF02
	Eszopiclone	N05CF04
	Clonazepam	N03AE01
	Alprazolam	N05BA12
	Diazepam	N05BA01
	Lorazepam	N05BA06
	-	
8.3. Sedating Antihistamines	Alimemazine	R06AD01
	Chlorpheniramine	R06AB04
	Cyproheptadine	R06AX02
	Hydroxyzine	N05BB01
	Ketotifen	R06AX17
	Promethazine	R06AD02

	Cetirizine	R06AE07	
	Dimenhydrinate	R06AA11	
	Diphenhydramine	R06AA02	
9. Baclofen	Baclofen	M03BX01	
10. Antipsychotics	Chlorpromazine	N05AA01	
	Methotrimeprazine	N05AA02	
	Fluphenazine	N05AB02	
	Perphenazine	N05AB03	
	Prochlorperazine	N05AB04	
	Trifluoperazine	N05AB06	
	Periciazine	N05AC01	
	Haloperidol	N05AD01	
	Ziprasidone	N05AE04	
	Lurasidone	N05AE05	
	Flupentixol	N05AF01	
	Zuclopenthixol	N05AF05	
	Pimozide	N05AG02	
	Loxapine	N05AH01	
	Clozapine	N05AH02	
	Olanzapine	N05AH03	
	Quetiapine	N05AH04	
	Asenapine	N05AH05	
	Risperidone	N05AX08	
	Aripiprazole	N05AX12	
	Paliperidone	N05AX13	
	Cariprazine	N05AX15	
	Brexpiprazole	N05AX16	
	<u> </u>		
11. Lithium	Lithium	N05AN01	
12. Tricyclic antidepressants	Amitriptyline	N06AA09	
· -	Desipramine	N06AA01	
	Imipramine	N06AA02	
	Clomipramine	N06AA04	

	Trimipramine	N06AA06
	Nortriptyline	N06AA10
	Doxepin	N06AA12
13. Trazodone	Trazodone	N06AX05
14. Acetylcholinesterase	Donepezil	N06DA02
inhibitors	Rivastigmine	N06DA03
	Galantamine	N06DA04
	Neostigmine	N07AA01
	Pyridostigmine	N07AA02
15. Oxybutinin	Oxybutynin	G04BD04
16. GI Medications	Metoclopramide	A03FA01
	Domperidone	A03FA03
	Misoprostol	A02BB01
	Cimetidine	A02BA01
	Ranitidine	A02BA02
	Famotidine	A02BA03
	Nizatidine	A02BA04
	Omeprazole	A02BC01
	Pantoprazole	A02BC02
	Lansoprazole	A02BC03
	Rabeprazole	A02BC04
	Esomeprazole	A02BC05
	Dexlansoprazole	A02BC06
	Sucralfate	A02BX02
	Trimebutine	A03AA05
	Dicyclomine	A03AA07
	Glycopyrronium	A03AB02
	Papaverine	A03AD01
	Pinaverium	A03AX04
17. Other (quinine, supplements	Quinine	P01BC01
melatonin, etc)	Melatonin	N05CH01
18.		

IMPROVE-IT Patient Screening Page 1

# **IMPROVE-IT HRM Capacity to Consent**

Record ID	
This participant is not eligible. This form can only be comporiteria.	pleted for participants who meet the preliminary eligibility
Screening ID [screen_id]	
Start time:	
I will now ask you a few questions to make sur	e you understand the study.
Is this a research study or is it part of the regular treatment that the hospital provides?	Regular treatment     Research study
What is the purpose of the study that was just described to you?	O I don't know/ No clue Partial response regarding medication/treatment (without mention of medication)
Interviewer: Allow patient to answer and prompt for additional answers as at least 2 responses are required.	management/coordinated care)  *One of the field notes examples or similar*  (*Coordinate care/communication from hospital to home *Improve medication safety or medication management *Better communication with my provide about my medications *Help prevent complications related to taking multiple medications *High-risk medications *Other reasonable response)

What aspects of the study described might encourage you to participate?	<ul> <li>I don't know</li> <li>Partial response regarding treatment, follow-up</li> <li>*At least one of the specific themes in field note examples, or similar*</li> </ul>			
Interviewer: Allow patient to answer and prompt for additional answers if required as at least 2 responses are required.	(*Medication review with the doctor or pharmacist *Help me understand what is going on with my medications *Avoid confusion about my medications when I get discharged back home *Get advice about my medications and have my questions answered *Better communication with my doctors and specialists, so that they understand what happened and what is going on with my medications *Other reasonable response)			
Do you have to be in this study if you do not want to participate?	<ul><li>Yes or don't know</li><li>No</li></ul>			
If you withdraw from this study, will you still be able to receive regular medical care?	○ Yes ○ No			

Can you tell us a couple of things that you will be asked to do if you participate in the study??  Interviewer: Allow patient to answer and prompt for additional answers if required as at least 2 responses are required.	<ul> <li>○ I don't know/no correct response</li> <li>○ Only one of the below field note examples</li> <li>○ *At least two of the following field note examples or similar*</li> <li>(*Go through my medications with the doctor or pharmacist *Answer some questionnaires at the beginning of the study *Participate in phone visits with doctor/pharmacist about my medications at different time points *Answer questions at the end of study *Other reasonable response)</li> </ul>
What might be some risks or downsides involved with participating in this study?	<ul> <li>I don't know</li> <li>Partial response with generalities (eg, 'waste of time', 'too many phone calls', etc</li> <li>*One of the themes listed in the field note or</li> </ul>
Interviewer: Allow patient to answer and prompt for additional answers if required as at least 2 responses are required.	similar* (*Inconvenience or hassle of research coordinators phoning me at three different time points *Time commitment involved at the beginning or with the phone calls *Potential for privacy breach of my personal health information *Too many people involved in my care *Other reasonable response)
Can you describe some of the benefits that you may gain by participating in this study??	O I don't know Partial response on only one of the themes listed in field notes
Interviewer: Allow patient to answer and prompt for additional answers if required as at least 2 responses are required.	*At least one of the field note examples or similar*  (*Avoiding complications with my medications *Help from a doctor/pharmacist with managing my medications *Understanding my medications better *Getting advice on what to do after I go home from the hospital *Better communication with my doctors about what is going on with my medications *Other reasonable response)
Is it possible that being in this study will not have any benefit to you personally?	○ No, or don't know ○ Yes

To	 _	~	$\sim$	,	^
	_				_

					_
(Threshol	ld to	enroll.	・1つ	/12\	

REDCap Form Completion Details					
Form entered and completed by:	<ul><li>○ Victoria Telford</li><li>○ Research Assistant</li></ul>				
Date of Form Completion:					
Time form completed					